e-learning
resources
Munich 2006
Monday 04.09.2006
Pulmonary hypertension: diagnostic tools and therapeutic approaches
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
A potential role for sildenafil in the management of pulmonary hypertension associated with parenchymal lung disease
B. P. Madden, T. K. Loke, M. Allenby, A. Sheth (London, United Kingdom)
Source:
Annual Congress 2006 - Pulmonary hypertension: diagnostic tools and therapeutic approaches
Session:
Pulmonary hypertension: diagnostic tools and therapeutic approaches
Session type:
Thematic Poster Session
Number:
2487
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. P. Madden, T. K. Loke, M. Allenby, A. Sheth (London, United Kingdom). A potential role for sildenafil in the management of pulmonary hypertension associated with parenchymal lung disease. Eur Respir J 2006; 28: Suppl. 50, 2487
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Imaging of complicated pneumonia: what is new?
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Bosentan for sarcoidosis associated pulmonary arterial hypertension (BoSAPH) was effective in advanced parenchymal lung disease
Source: Annual Congress 2012 - Sarcoidosis
Year: 2012
The effect of lung diseases on pulmonary hypertension and the effect of pulmonary hypertension on the lung
Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond
Year: 2021
Biomarkers in pulmonary hypertension associated to interstitial lung disease
Source: Annual Congress 2010 - Pulmonary circulation II
Year: 2010
Clinical characteristics, haemodynamics, and survival in patients with combined pulmonary fibrosis and emphysema and associated pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary vascular medicine
Year: 2008
Can ADMA play a role in determining pulmonary hypertension related to chronic obstructive lung disease?
Source: International Congress 2016 – Pulmonary hypertension in lung disease
Year: 2016
Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension
Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases
Year: 2020
Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension
Source: Eur Respir J, 55 (6) 2000041; 10.1183/13993003.00041-2020
Year: 2020
The change of lung diffusion capacity does not influence the prognosis in patients with pulmonary arterial hypertension associated with systemic sclerosis.
Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension
Year: 2019
Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry
Source: Eur Respir J, 58 (2) 2101483; 10.1183/13993003.01483-2021
Year: 2021
Is sildenafil an effective bridging therapy to lung transplantation for patients with pulmonary hypertension in the setting of lung disease?
Source: International Congress 2015 – Pulmonary hypertension in lung disease
Year: 2015
Determination of pulmonary hypertension degree in patients with interstitial lung diseases
Source: Annual Congress 2010 - Different patterns of interstitial lung disease
Year: 2010
Sildenafil is a potent pulmonary vasodilator in pulmonary hypertension associated with interstitial lung disease: impact on gas exchange properties
Source: Eur Respir J 2002; 20: Suppl. 38, 598s
Year: 2002
Is inflammation a potential therapeutic target in chronic thromboembolic pulmonary hypertension?
Source: Eur Respir J 2014; 44: 842-845
Year: 2014
Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis
Source: Eur Respir J 2012; 40: 93-100
Year: 2012
Risk assessment in severe pulmonary hypertension due to interstitial lung disease
Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases
Year: 2020
Pulmonary hypertension in patients with interstitial lung disease
Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases
Year: 2011
Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema
Source: Eur Respir J 2011; 37: 176-183
Year: 2011
Novel treatment for pulmonary vascular disease: lessons from pathophysiology
Source: Annual Congress 2006 - Molecular pathology: an approach to lung diseases
Year: 2006
Treatment of pulmonary hypertension in chronic obstructive pulmonary disease
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=313
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept